Artivion, Inc.
As of Oct 22, 2026, Artivion is in Stage 4, the downtrend phase, now in week 3 (since Oct 5, 2026). It closed at $23.97, 49.7% below its 52-week high and below its 200-day average, which is falling.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is AORT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AORT among Medical Devices84th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …84 | AORT | Stage 4 · wk 3 | 26 | +1.9% |
Artivion: quick answers
What stage is Artivion in?
As of Oct 22, 2026, Artivion (AORT) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 5, 2026 and is in week 3. What the four stages mean
Is Artivion in an uptrend?
No. Artivion is in a Stage 4 downtrend. It trades 20.1% below its 200-day average, which is falling.
How far is Artivion from its 52-week high?
Artivion closed at $23.97 on Oct 22, 2026, 49.7% below its 52-week high of $47.63. Its 52-week low is $20.10.
How has Artivion performed over the past year?
As of Oct 22, 2026, Artivion is down 43.3% over the past year and down 46.1% so far in 2026.
Which sector and industry is Artivion in?
Artivion is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.